Joerg Kleiber
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joerg Kleiber.
The Journal of Molecular Diagnostics | 2000
Joerg Kleiber; Thomas Walter; Gerd Haberhausen; Sue Tsang; Reiner Babiel; Maurice Rosenstraus
We developed a homogeneous format reverse transcription-polymerase chain reaction assay for quantitating hepatitis C virus (HCV) RNA based on the TaqMan principle, in which signal is generated by cleaving a target-specific probe during amplification. The test uses two probes, one specific for HCV and one specific for an internal control, containing fluorophores with different emission spectra. Titers are calculated in international units (IU)/ml by comparing the HCV signal generated by test samples to that generated by a set of external standards. Endpoint titration experiments demonstrated that samples containing 28 IU/ml give positive results 95% of the time. Based on these data, the limit of detection was set conservatively at 40 IU/ml. All HCV genotypes were amplified with equal efficiency and accurately quantitated: when equal quantities of RNA were tested, each genotype produced virtually identical fluorescent signals. The test exhibited a linear range extending from 64 to 4,180,000 IU/ml and excellent reproducibility, with coefficients of variation ranging from 21.6 to 30.4%, which implies that titers that differ by a factor of twofold (0.3 log10) are statistically significant (P = 0.005). The test did not react with other organisms likely to co-infect patients with hepatitis C and exhibited a specificity of 99% when evaluated on a set of samples from HCV seronegative blood donors. In interferon-treated patients, the patterns of viral load changes revealed by the TaqMan HCV quantitative test distinguished responders from nonresponders and responder-relapsers. These data indicate that the TaqMan quantitative HCV test provides an attractive alternative for measuring HCV viral load and should prove useful for prognosis and for monitoring the efficacy of antiviral treatments.
Archive | 1998
Joerg Kleiber; Christine Markert-Hahn; Herbert Harttig
Archive | 2005
Dirk Block; Ruediger Haenel; Joerg Kleiber; Manuela Poignee-Heger; Thomas Walter; Ralf Zielenski
Archive | 1998
Joerg Kleiber; Karim Tabiti; Gregor Sagner
Archive | 1998
Joerg Kleiber; Christine Markert-Hahn; Herbert Harttig
Archive | 2007
Herbert Harttig; Joerg Kleiber; Christine Markert-Hahn; クライベル,イェルク; ハルトティーク,ヘルベルト; マルケルト−ハーン,クリスティーネ
Archive | 2006
Dirk Block; Frank Bergmann; Joerg Kleiber; Friedemann Krause; Christine Markert-Hahn
Archive | 2009
Frank Bergmann; Dirk Block; Joerg Kleiber; Christine Market-Hahn; クライベル,イェルク; ブロック,ディルク; ベルクマン,フランク; マルケト−ハーン,クリスティーネ
Archive | 2005
Dirk Block; Ruediger Haenel; Manuela Poignee-Heger; Thomas Walter; Joerg Kleiber; Ralf Zielenski
Archive | 2005
Dirk Block; Ruediger Haenel; Joerg Kleiber; Manuela Poignee-Heger; Thomas Walter; Ralf Zielenski